239 related articles for article (PubMed ID: 25916431)
1. Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.
Cannavo S; Bogazzi F; Colao A; De Marinis L; Maffei P; Gomez R; Graziano E; Monterubbianesi M; Grottoli S;
J Endocrinol Invest; 2015 Oct; 38(10):1099-109. PubMed ID: 25916431
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.
van der Lely AJ; Biller BM; Brue T; Buchfelder M; Ghigo E; Gomez R; Hey-Hadavi J; Lundgren F; Rajicic N; Strasburger CJ; Webb SM; Koltowska-Häggström M
J Clin Endocrinol Metab; 2012 May; 97(5):1589-97. PubMed ID: 22362824
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY.
Freda PU; Gordon MB; Kelepouris N; Jonsson P; Koltowska-Haggstrom M; van der Lely AJ
Endocr Pract; 2015 Mar; 21(3):264-74. PubMed ID: 25370326
[TBL] [Abstract][Full Text] [Related]
4. The German ACROSTUDY: past and present.
Buchfelder M; Schlaffer S; Droste M; Mann K; Saller B; Brübach K; Stalla GK; Strasburger CJ;
Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S3-S10. PubMed ID: 19684061
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
6. Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY.
Chanson P; Brue T; Delemer B; Caron P; Borson-Chazot F; Zouater H;
Ann Endocrinol (Paris); 2015 Dec; 76(6):664-70. PubMed ID: 26596374
[TBL] [Abstract][Full Text] [Related]
7. Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY.
Brue T; Castinetti F; Lundgren F; Koltowska-Häggström M; Petrossians P;
Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S11-7. PubMed ID: 19684051
[TBL] [Abstract][Full Text] [Related]
8. [Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly].
Zgliczyński W; Zdunowski P
Endokrynol Pol; 2007; 58(5):408-16. PubMed ID: 18058736
[TBL] [Abstract][Full Text] [Related]
9. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
10. Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant.
Strasburger CJ; Mattsson A; Wilton P; Aydin F; Hey-Hadavi J; Biller BMK
Eur J Endocrinol; 2018 Apr; 178(4):321-329. PubMed ID: 29371335
[TBL] [Abstract][Full Text] [Related]
11. All-cause mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis.
Tritos NA; Mattsson AF; Vila G; Biller BMK; Klibanski A; Valluri S; Hey-Hadavi J; Kelepouris N; Jimenez C
Eur J Endocrinol; 2020 Mar; 182(3):285-292. PubMed ID: 31917681
[TBL] [Abstract][Full Text] [Related]
12. Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY.
Bernabeu I; Pico A; Venegas E; Aller J; Alvarez-Escolá C; García-Arnés JA; Marazuela M; Jonsson P; Mir N; García Vargas M;
Pituitary; 2016 Apr; 19(2):127-37. PubMed ID: 26553421
[TBL] [Abstract][Full Text] [Related]
13. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
14. ACROSTUDY: Status Update on 469 Patients.
Brue T
Horm Res; 2009 Jan; 71 Suppl 1():34-8. PubMed ID: 19153503
[TBL] [Abstract][Full Text] [Related]
15. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly.
Bernabeu I; Alvarez-Escolá C; Quinteiro C; Lucas T; Puig-Domingo M; Luque-Ramírez M; de Miguel-Novoa P; Fernandez-Rodriguez E; Halperin I; Loidi L; Casanueva FF; Marazuela M
J Clin Endocrinol Metab; 2010 Jan; 95(1):222-9. PubMed ID: 19850678
[TBL] [Abstract][Full Text] [Related]
16. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study.
Schreiber I; Buchfelder M; Droste M; Forssmann K; Mann K; Saller B; Strasburger CJ;
Eur J Endocrinol; 2007 Jan; 156(1):75-82. PubMed ID: 17218728
[TBL] [Abstract][Full Text] [Related]
17. Lessons from 6 years of GH receptor antagonist therapy for acromegaly.
Trainer PJ
J Endocrinol Invest; 2003; 26(10 Suppl):44-52. PubMed ID: 15497659
[TBL] [Abstract][Full Text] [Related]
18. Pegvisomant in the treatment of acromegaly.
Parkinson C; Scarlett JA; Trainer PJ
Adv Drug Deliv Rev; 2003 Sep; 55(10):1303-14. PubMed ID: 14499709
[TBL] [Abstract][Full Text] [Related]
19. A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly.
Ezzat S; Gaspo R; Serri O; Ur E; Chik CL
Clin Invest Med; 2009 Dec; 32(6):E265. PubMed ID: 20003832
[TBL] [Abstract][Full Text] [Related]
20. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
